Vir Biotechnology, Inc. today announced that Week 48 endpoint analysis from the Company's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Moderna posted a loss of 51 cents a share for the third quarter, down from a profit of 3 cents last year, but narrower than ...

Moderna on Thursday also trimmed its adjusted operating expenses outlook for 2025 by $700 million to a range of $5.2 billion to $5.4 billion. Copyright 2025 Thomson Reuters.

Reports third quarter revenue of $1.0 billion, GAAP net loss of $ (0.2) billion and GAAP EPS of $ (0.51) Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 - $5.4 ...

The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.

"It is well recognized that human papillomavirus (HPV), hepatitis B virus, and other viruses can cause cancer; however, the ...

In the largest synthesis to date, researchers reviewed 155 studies linking viral infections, including influenza, SARS-CoV-2, ...

Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children's Research Institute, MelbourneMaking proteins with AI: Dr Rhys ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...

Covid-19 infections have been strongly linked with cardiovascular events like a heart disease and stroke, but new research ...

Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children’s Research Institute, Melbourne Making proteins with AI: Dr Rhys Grinter, Bio21 Institute, The ...